The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
The Pathology of Amyloidosis in Classification: A Review
Abstract
Background: The amyloidoses are a rare and heterogeneous group of disorders that are characterized by the deposition of abnormally folded proteins in tissues ultimately leading to organ damage. The deposits are mainly extracellular and are recognizable by their affinity for Congo red and their yellow-green birefringence under polarized light. Current classification of amyloid in medical practice is based on the amyloid protein type. To date, 36 proteins have been identified as being amyloidogenic in humans. Summary: in clinical practice, it is critical to distinguish between treatable versus non-treatable amyloidoses. Moreover, amyloidoses with a genetic component must be distinguished from the sporadic types and systemic amyloidoses must be distinguished from the localized forms. Among the systemic amyloidoses, AL continues to be the most common amyloid diagnosis in the developed world; other clinically significant types include AA, ALECT2, and ATTR. The latter is emerging as an underdiagnosed type in both the hereditary and wild-type setting. Other hereditary amyloidoses include AFib, several amyloidoses derived from apolipoproteins, AGel, ALys, etc. In a dialysis setting, systemic amyloid derived from β 2 microglobulin (Aβ2M) should be considered, although a very rare hereditary variant has also been reported; several amyloidoses may be typically associated with aging and several iatrogenic types have also emerged. Determination of the amyloid protein type is imperative before specific therapy can be implemented and the current methods are briefly summarized. A brief overview of the target organ involvement by amyloid type is also included. Key Messages: (1) Early diagnosis of amyloidosis continues to pose a significant challenge and requires the participation of many clinical and laboratory specialties. (2) Determination of the protein type is imperative before specific therapy can be implemented. (3) While mass spectrometry has emerged as the preferred method of amyloid typing, careful application of immune methods is still clinically useful but caution and experience, as well as awareness of the limitations of each method, are necessary in their interpretation. (4) While the spectrum of amyloidoses continues to expand, it is critical to distinguish between those that are currently treatable versus those that are untreatable and avoid causing harm by inappropriate treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Grogan, M., Scott, C. G., Kyle, R. A., Zeldenrust, S. R., Gertz, M. A., Lin, G., Klarich, K. W., Miller, W. L., Maleszewski, J. J., & Dispenzieri, A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.033 · Cited by 763
Maurer, M. S., Bokhari, S., Damy, T., Dorbala, S., Drachman, B. M., Fontana, M., Grogan, M., Kristen, A. V., Lousada, I., Nativi-Nicolau, J., et al. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006075 · Cited by 568
Benson, M. D., Buxbaum, J. N., Eisenberg, D. S., Merlini, G., Saraiva, M. J. M., Sekijima, Y., Sipe, J. D., & Westermark, P. (2018) · Amyloid · doi:10.1080/13506129.2018.1549825 · Cited by 566
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.596 · Cited by 538
Epidemiology of AL amyloidosis: a real-world study using US claims data
Quock, T. P., Yan, T., Chang, E., Guthrie, S., & Broder, M. S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016402 · Cited by 416
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
Sperry, B. W., Reyes, B. A., Ikram, A., Donnelly, J. P., Phelan, D., Jaber, W. A., Shapiro, D., Evans, P. J., Maschke, S., Kilpatrick, S. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.092 · Cited by 358
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
Adams, D., Ando, Y., Beirão, J. M., Coelho, T., Gertz, M. A., Gillmore, J. D., Hawkins, P. N., Lousada, I., Suhr, O. B., & Merlini, G. (2021) · Journal of Neurology · doi:10.1007/s00415-019-09688-0 · Cited by 314
Renal Amyloidosis: Origin and Clinicopathologic Correlations of 474 Recent Cases
Said, S. M., Sethi, S., Valeri, A. M., Leung, N., Cornell, L. D., Fidler, M. E., Herrera Hernandez, L., Vrana, J. A., Theis, J. D., Quint, P. S., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10491012 · Cited by 284
AA Amyloidosis: Pathogenesis and Targeted Therapy
Westermark, G. T., Fändrich, M., & Westermark, P. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163913 · Cited by 264
Damy, T., Costes, B., Hagège, A. A., Donal, E., Eicher, J.-C., Slama, M., Guellich, A., Rappeneau, S., Gueffet, J.-P., Logeart, D., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv583 · Cited by 247
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Gertz, M. A. (2014) · American Journal of Hematology · doi:10.1002/ajh.23828 · Cited by 245
Parman, Y., Adams, D., Obici, L., Galán, L., Guergueltcheva, V., Suhr, O. B., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000288 · Cited by 238
Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis
Quarta, C. C., Gonzalez-Lopez, E., Gilbertson, J. A., Botcher, N., Rowczenio, D., Petrie, A., Rezk, T., Youngstein, T., Mahmood, S., Sachchithanantham, S., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx047 · Cited by 227
Papa, R., & Lachmann, H. J. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.004 · Cited by 199
Vrana, J. A., Theis, J. D., Dasari, S., Mereuta, O. M., Dispenzieri, A., Zeldenrust, S. R., Gertz, M. A., Kurtin, P. J., Grogg, K. L., & Dogan, A. (2014) · Haematologica · doi:10.3324/haematol.2013.102764 · Cited by 190
Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African–Americans
Jacobson, D. R., Alexander, A. A., Tagoe, C., & Buxbaum, J. N. (2015) · Amyloid · doi:10.3109/13506129.2015.1051219 · Cited by 183
Leukocyte chemotactic factor 2: A novel renal amyloid protein
Benson, M. D., James, S., Scott, K., Liepnieks, J. J., & Kluve-Beckerman, B. (2008) · Kidney International · doi:10.1038/ki.2008.152 · Cited by 173
Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain Amyloidosis
Gillmore, J. D., Lachmann, H. J., Rowczenio, D. M., Gilbertson, J. A., Zeng, C., Liu, Z.-H., Leishi, L., Wechalekar, A. D., & Hawkins, P. N. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060614 · Cited by 172
Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)
Phull, P., Sanchorawala, V., Connors, L. H., Doros, G., Ruberg, F. L., Berk, J. L., & Sarosiek, S. (2018) · Amyloid · doi:10.1080/13506129.2018.1436048 · Cited by 165
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable
Rubin, J., & Maurer, M. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-052918-020140 · Cited by 165
Yanagisawa, A., Ueda, M., Sueyoshi, T., Okada, T., Fujimoto, T., Ogi, Y., Kitagawa, K., Tasaki, M., Misumi, Y., Oshima, T., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.102 · Cited by 161
Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis
Fine, N. M., Arruda-Olson, A. M., Dispenzieri, A. A., Zeldenrust, S. R., Gertz, M. A., Kyle, R. A., Swiecicki, P. L., Scott, C. G., & Grogan, M. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.030 · Cited by 148
Suhr, O. B., Lundgren, E., & Westermark, P. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12585 · Cited by 143
Stangou, A. J., Banner, N. R., Hendry, B. M., Rela, M., Portmann, B. C., Wendon, J. A., Monaghan, M. J., MacCarthy, P. A., Buxton-Thomas, M. S., Mathias, C. J., et al. (2009) · Blood · doi:10.1182/blood-2009-06-223792 · Cited by 142
Siepen, F. A. D., Hein, S. J., Prestel, S., Baumgärtner, C., Schönland, S. O., Hegenbart, U., Röcken, C., Katus, H. A., & Kristen, A. V. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01467-1 · Cited by 142
Gilbertson, J. A., Theis, J. D., Vrana, J. A., Lachmann, H. J., Wechalekar, A. D., Whelan, C. J., Hawkins, P. N., Doǧan, A., & Gillmore, J. D. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202722 · Cited by 138
Freudenthaler, S., Hegenbart, U., Schönland, S. O., Behrens, H., Krüger, S., & Röcken, C. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1916-y · Cited by 135
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
Gertz, M. A. (2018) · American journal of hematology/oncology · doi:10.1002/ajh.25149 · Cited by 130
Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis
Said, S. M., Sethi, S. M., Valeri, A. M., Chang, A., Nast, C. C., Krahl, L., Molloy, P. J., Barry, M., Fidler, M. E., Cornell, L. D., et al. (2014) · Kidney International · doi:10.1038/ki.2013.558 · Cited by 117
Amyloidosis: Insights from Proteomics
Doǧan, A. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100200 · Cited by 109
Advances in the treatment of hereditary transthyretin amyloidosis: a review
Gertz, M. A., Mauermann, M. L., Grogan, M., & Coelho, T. (2019) · Brain and Behavior · doi:10.1002/brb3.1371 · Cited by 102
Systemic amyloidosis: novel therapies and role of biomarkers
Nuvolone, M., & Merlini, G. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw305 · Cited by 95
Nasr, S. H., Doǧan, A., & Larsen, C. P. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12551214 · Cited by 84
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis
Rezk, T., Gilbertson, J. A., Mangione, P. P., Rowczenio, D. M., Rendell, N. B., Canetti, D., Lachmann, H. J., Wechalekar, A. D., Bass, P., Hawkins, P. N., et al. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.126 · Cited by 77
Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution
Said, S. M., Grogg, K. L., & Smyrk, T. C. (2015) · Human Pathology · doi:10.1016/j.humpath.2014.12.009 · Cited by 75
Transthyretin Cardiac Amyloidosis in Older Americans
Brunjes, D. L., Castaño, A., Clemons, A. M., Rubin, J. N., & Maurer, M. S. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.10.008 · Cited by 69
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis
Rezk, T., Gilbertson, J. A., Rowczenio, D. M., Bass, P., Lachmann, H. J., Wechalekar, A. D., Fontana, M., Mahmood, S., Sachchithanantham, S., Whelan, C. J., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw375 · Cited by 50
Larsen, C. P., Beggs, M. L., Wilson, J. D., & Lathrop, S. L. (2016) · Amyloid · doi:10.3109/13506129.2016.1145110 · Cited by 49
Fibrinogen alpha amyloidosis: insights from proteomics
Chapman, J. R., & Doǧan, A. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1659137 · Cited by 46
Globular Hepatic Amyloid Is Highly Sensitive and Specific for LECT2 Amyloidosis
Chandan, V. S., Shah, S., Lam-Himlin, D. M., Petris, G. D., Mereuta, O. M., Doǧan, A., Torbenson, M. S., & Wu, T. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000373 · Cited by 45
Obesity is a significant susceptibility factor for idiopathic AA amyloidosis
Blank, N., Hegenbart, U., Dietrich, S., Brune, M., Beimler, J., Röcken, C., Müller‐Tidow, C., Lorenz, H., & Schönland, S. O. (2018) · Amyloid · doi:10.1080/13506129.2018.1429391 · Cited by 39
Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains
Misra, P., Blancas‐Mejía, L. M., & Ramírez-Alvarado, M. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00311 · Cited by 33
Fayyaz, A. U., Bois, M. C., Dasari, S., Padmanabhan, D., Vrana, J. A., Stulak, J. M., Edwards, W. D., Kurtin, P. J., Asirvatham, S. J., Grogan, M. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0407-5 · Cited by 24
Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017
Prada, V., Massucco, S., Venturi, C. B., Geroldi, A., Bellone, E., Mandich, P., Minuto, M. N., Varaldo, E., Mancardi, G., Grandis, M., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01218 · Cited by 24
Systemic amyloidoses and proteomics: The state of the art
Lavatelli, F., Fonzo, A. D., Palladini, G. O., & Merlini, G. (2016) · EuPA Open Proteomics · doi:10.1016/j.euprot.2016.02.003 · Cited by 22
Thioflavin T Stain: An Easier and More Sensitive Method for Amyloid Detection
Picken, M. M., & Herrera, G. A. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_15 · Cited by 19
Self-citationLocalized Amyloidoses and Amyloidoses Associated with Aging Outside the Central Nervous System
Westermark, P. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_7 · Cited by 10
Cited by
AmyloGram reveals amyloidogenic potential in stroke thrombus proteomes
Kell, D. B., Doyle, K. M., Salcedo-Sora, J. E., Sekhar, A., Walker, M., & Pretorius, E. (2025) · Biochemical Journal · doi:10.1042/bcj20253317 · Cited by 4
Metadata
- Authors
- Picken, M. M.
- Venue
- Acta Haematologica
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 143
- Issue
- 4
- Pages
- 322-334
- ISSN
- 0001-5792 (ISSN-L)
- 1421-9662
- OpenAlex
- W3023704686
- Cited by
- 313
- References
- 51
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.